Immunovant flashes secret data behind potential Roivant buyout, but investors see a difficult future
The “non-public information” that made Roivant want to acquire their troubled Immunovant spinout at a potentially substantial premium just became public. But neither investors nor analysts agreed with Roivant’s spin on the data, selling off shares of $IMVT by nearly 40% Thursday
Immunovant announced Tuesday that they saw a path forward for bringing their lead and only drug back into development, after safety issues forced the company to pause its only two active trials over the winter. They now plan to launch a pivotal trial for the rare disease myasthenia gravis by early 2022, while adding three mid-stage studies for other autoimmune disorders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
